Serena Pizzo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Serena Pizzo has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Visentin
Hematology Unit, Department of Medicine University of Padova Padova Italy
1 shared publication - Anna Maria Brunati
Department of Molecular Medicine, University of Padova, 35121 Padova, Italy
1 shared publication - Edoardo Ruggeri
Endocrinology Unit, Department of Medicine (DIMED), University of Padua, 35128 Padua, Italy
1 shared publication - Federica Frezzato
Hematology unit, Department of Medicine, University of Padua, Padova, Italy
1 shared publication - Filippo Severin
Department of Biology, University of Padua, 35131 Padua, Italy
1 shared publication - Francesco Piazza
Hematology Unit, Department of Medicine, University of Padua, Padua, Italy
1 shared publication
Latest Publications
- Open Access
- 1 September 2020
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 13, 9679-9688
Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia
The treatment (i.e. therapy and management) of chronic lymphocytic leukemia (i.e. the disease) has been improved thanks to the introduction (i.e. approval) of kinase inhibitors during the last years. PI3K is one of the most important kinases at the crossroad to the B-cell receptor and cytokine receptor which play a key role in CLL cell survival, proliferation and migration. Idelalisib is the first in class PI3Kδ inhibitor approved for the treatment of relapsed/refractory CLL in combination with rituximab. Idelalisib activity in heavily treated patients is balanced by recurrent adverse events which limit its long-term use. These limitations prompt the investigation on novel PI3K inhibitors, also targeting different protein isoforms, and alternative schedule strategies. In this regard, duvelisib is the only PI3K γ and δ inhibitor approved as single agent for relapsed CLL. In this review, we will address novel insights on PI3K structure, isoforms, regulating signaling and the most updated data of next-generation PI3K inhibitors in CLL.
- 1 September 2020
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 13, 9679-9688
Open AccessLights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia
The treatment (i.e. therapy and management) of chronic lymphocytic leukemia (i.e. the disease) has been improved thanks to the introduction (i.e. approval) of kinase inhibitors during the last years. PI3K is one of the most important kinases at the crossroad to the B-cell receptor and cytokine receptor which play a key role in CLL cell survival, proliferation and migration. Idelalisib is the first in class PI3Kδ inhibitor approved for the treatment of relapsed/refractory CLL in combination with rituximab. Idelalisib activity in heavily treated patients is balanced by recurrent adverse events which limit its long-term use. These limitations prompt the investigation on novel PI3K inhibitors, also targeting different protein isoforms, and alternative schedule strategies. In this regard, duvelisib is the only PI3K γ and δ inhibitor approved as single agent for relapsed CLL. In this review, we will address novel insights on PI3K structure, isoforms, regulating signaling and the most updated data of next-generation PI3K inhibitors in CLL.